A	B	C	D	E	F	G	H
1	Main
2		Brand Name	Viread
3		Generic Name	tenofovir
4		Indication	HIV, HBV
5			250,000 US patients who are undiagnosed.
6			1.0m-1.2m patients with HIV in the US. 750k-900k are diagnosed. 500k are on ARV. 310k are on tenofovir.
7		Price	7% increase as of 4/1/06. $482/mo - Q2 2007
8		IP	5922695 - Issued 6/13/99, Filed 6/25/97.
9		Clinical Trials
10			Study 934 - HIV - 3-year data coming up at IAS
11			96-week data comparing Viread/Emtriva/Sustiva to Combivir/Sustiva
12			75% vs 62% efficacy superiority (p=0.004)
13			7% is due to AE withdrawal and >4% is due to virologic rebound
14			SS increase in limb fat in Viread and a SS decrease in Combivir. This demonstrates less lipodystrophy than Combivir.
15
16			Study 903 - 5-year data at IAS
17
18
19
20			Phase III HBV n=375 - Study 102
21			Met primary endpoint of non-inferiority to Hepsera in HBV-e-antigen-negative patients.
22			70.8% complete response for Viread vs 48.8% for Hepsera (nodal score and viral load reduction).
23
24			Phase III HBV - Study 103
25			e-antigen-positive patients, which are harder.
26			Same endpoint - 66.5% vs 12.2% response rate.
27
28
29				NDC			Combivir	Epivir
30				TRx	TRx %		TRx %	TRx
31			1/12/2007	9707	0.121		0.138	0.08
32			1/5/2007	9456	0.125		0.14	0.083
33
34
35
36			Phase III CAPRISA 004
37
38			Phase III iPrEx